Skip to main content
. 2020 Jul 27;31(2):178–186. doi: 10.1038/s41422-020-0375-9

Fig. 1. The FUTURE trial schema: integrating TNBC subtyping and genomic targeting.

Fig. 1

n, number of the patients; TNBC, triple-negative breast cancer; FUSCC, Fudan University Shanghai Cancer Center; LAR, luminal androgen receptor; IM, immunomodulatory; BLIS, basal-like immune-suppressed; MES, mesenchymal-like; AR, androgen receptor; PD-1, programmed cell death-1; PARPi, poly ADP-ribose polymerase inhibitor; VEGFR, vascular endothelial growth factor receptor.